Next-gen STI vaccines target herpes, HIV, and gonorrhea. mRNA technology (used in COVID vaccines) is being tested for HSV-2. A gonorrhea vaccine trial in 2023 showed 40% efficacy. HIV vaccine research focuses on broadly neutralizing antibodies. Global funding is critical to accelerate trials.

